>
Switch to:

Allergy Therapeutics Asset Turnover

: 0.33 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Allergy Therapeutics's Revenue for the six months ended in Jun. 2021 was $42.5 Mil. Allergy Therapeutics's Total Assets for the quarter that ended in Jun. 2021 was $128.3 Mil. Therefore, Allergy Therapeutics's Asset Turnover for the quarter that ended in Jun. 2021 was 0.33.

Asset Turnover is linked to ROE % through Du Pont Formula. Allergy Therapeutics's annualized ROE % for the quarter that ended in Jun. 2021 was -46.00%. It is also linked to ROA % through Du Pont Formula. Allergy Therapeutics's annualized ROA % for the quarter that ended in Jun. 2021 was -26.35%.


Allergy Therapeutics Asset Turnover Historical Data

The historical data trend for Allergy Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.29 1.21 1.01 1.02

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.66 0.31 0.60 0.33

Allergy Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Allergy Therapeutics's Asset Turnover for the fiscal year that ended in Jun. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2021 )/( (Total Assets (A: Jun. 2020 )+Total Assets (A: Jun. 2021 ))/ count )
=118.2762973352/( (107.91614518148+123.54698457223)/ 2 )
=118.2762973352/115.73156487685
=1.02

Allergy Therapeutics's Asset Turnover for the quarter that ended in Jun. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Jun. 2021 ))/ count )
=42.495091164095/( (133.0685483871+123.54698457223)/ 2 )
=42.495091164095/128.30776647966
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Allergy Therapeutics  (OTCPK:AGYTF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Allergy Therapeutics's annulized ROE % for the quarter that ended in Jun. 2021 is

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-33.809256661992/73.50350631136
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-33.809256661992 / 84.990182328191)*(84.990182328191 / 128.30776647966)*(128.30776647966/ 73.50350631136)
=Net Margin %*Asset Turnover*Equity Multiplier
=-39.78 %*0.6624*1.7456
=ROA %*Equity Multiplier
=-26.35 %*1.7456
=-46.00 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2021) net income data. The Revenue data used here is two times the semi-annual (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Allergy Therapeutics's annulized ROA % for the quarter that ended in Jun. 2021 is

ROA %(Q: Jun. 2021 )
=Net Income/Total Assets
=-33.809256661992/128.30776647966
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-33.809256661992 / 84.990182328191)*(84.990182328191 / 128.30776647966)
=Net Margin %*Asset Turnover
=-39.78 %*0.6624
=-26.35 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2021) net income data. The Revenue data used here is two times the semi-annual (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Allergy Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)